Table 1.
Demographic and Baseline Characteristics
| Characteristic | GXRa.m.(n=107) | GXR p.m.(n=114) | Placebo(n=112) |
|---|---|---|---|
| Mean (SD) age, y | 9.1 (1.77) | 9.3 (1.76) | 8.9 (1.78) |
| Sex, n (%) | |||
| Male | 72 (67.3) | 78 (68.4) | 85 (75.9) |
| Female | 35 (32.7) | 36 (31.6) | 27 (24.1) |
| Race, n (%) | |||
| White | 66 (61.7) | 68 (59.6) | 56 (50.0) |
| Black or African American | 38 (35.5) | 35 (30.7) | 47 (42.0) |
| Asian | 1 (0.9) | 0 | 1 (0.9) |
| American Indian or Alaska Native | 0 | 1 (0.9) | 0 |
| Other | 2 (1.9) | 10 (8.8) | 8 (7.1) |
| Mean (SD) body weight, lb | 77.95 (19.44) | 80.38 (20.91) | 75.79 (17.57) |
| Mean (SD) BMI, kg/m2 | 17.92 (2.42) | 18.25 (2.35) | 17.96 (2.33) |
| ADHD subtype, n (%) | |||
| Predominately inattentivea | 3 (2.8) | 3 (2.6) | 1 (0.9) |
| Predominately hyperactive-impulsive | 3 (2.8) | 2 (1.8) | 1 (0.9) |
| Combined subtype | 101 (94.4) | 109 (95.6) | 110 (98.2) |
| Mean (SD) time since ADHD diagnosis, y | 1.5 (2.12) | 2.0 (2.24) | 1.6 (2.13) |
a
Predominately inattentive subtype was exclusionary.
ADHD, attention-deficit/hyperactivity disorder; BMI, body mass index; GXR, guanfacine extended release; SD, standard deviation.
Reprinted from Journal of the American Academy of Child & Adolescent Psychiatry 52(9), Jeffrey H. Newcorn, Mark A. Stein, Ann C. Childress, Sharon Youcha, Carla White, Gail Enright, and Jonathan Rubin, Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: Morning or evening administration, 921–930, ©2013, with permission from Elsevier.